

William Pao

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11352938/william-pao-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

45,793
citations

92
h-index

168
g-index

168
ext. papers

50,498
ext. citations

10.9
avg, IF

7.06
L-index

#	Paper	IF	Citations
160	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 13306-11	11.5	3659
159	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. <i>PLoS Medicine</i> , 2005 , 2, e73	11.6	2628
158	Somatic mutations affect key pathways in lung adenocarcinoma. <i>Nature</i> , 2008 , 455, 1069-75	50.4	2280
157	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. <i>Clinical Cancer Research</i> , 2013 , 19, 2240-7	12.9	1655
156	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20932-7	11.5	1395
155	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell</i> , 2012 , 150, 1107-20	20	1304
154	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. <i>Cancer Discovery</i> , 2014 , 4, 1046-61	24.4	1242
153	ROS1 rearrangements define a unique molecular class of lung cancers. <i>Journal of Clinical Oncology</i> , 2012 , 30, 863-70	2.2	1170
152	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. <i>PLoS Medicine</i> , 2005 , 2, e17	11.6	1160
151	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1998-2006	27.4	1042
150	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1104-10	36.3	919
149	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007 , 450, 893-8	50.4	900
148	New driver mutations in non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 175-80	21.7	881
147	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. <i>Nature Reviews Cancer</i> , 2010 , 10, 760-74	31.3	802
146	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. <i>Clinical Cancer Research</i> , 2006 , 12, 6494-501	12.9	677
145	Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1103-9	2.2	670
144	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. <i>Science Translational Medicine</i> , 2010 , 2, 62ra93	17.5	646

143	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6251-66	2.2	619
142	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 357-60	2.2	615
141	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2006 , 12, 839-44	12.9	597
140	Acquired resistance to TKIs in solid tumours: learning from lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 473-81	19.4	591
139	Anchored multiplex PCR for targeted next-generation sequencing. <i>Nature Medicine</i> , 2014 , 20, 1479-84	50.5	536
138	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. <i>Cancer Discovery</i> , 2012 , 2, 922-33	24.4	528
137	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2556-68	2.2	525
136	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3846-56	15.9	512
135	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. <i>Cancer Discovery</i> , 2013 , 3, 1404-15	24.4	493
134	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 11011-6	11.5	487
133	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. <i>Clinical Cancer Research</i> , 2011 , 17, 1616-22	13.9	470
132	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. <i>Clinical Cancer Research</i> , 2011 , 17, 1169-80	12.9	467
131	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 5731-4	12.9	429
130	PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. <i>Cancer Research</i> , 2009 , 69, 3256-61	10.1	411
129	KRAS mutations in non-small cell lung cancer. <i>Proceedings of the American Thoracic Society</i> , 2009 , 6, 201-5		399
128	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. <i>Science Translational Medicine</i> , 2011 , 3, 90ra59	17.5	383
127	RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4352-9	2.2	376
126	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2127-33	11.5	366

125	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. <i>Genes and Development</i> , 2006 , 20, 1496-510	12.6	363
124	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1070-80	2.2	362
123	Update on epidermal growth factor receptor mutations in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7232-41	12.9	315
122	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. <i>Cancer Discovery</i> , 2014 , 4, 1036-45	24.4	302
121	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 5530-7	12.9	282
120	Somatic mutations of the Parkinson disease-associated gene PARK2 in glioblastoma and other human malignancies. <i>Nature Genetics</i> , 2010 , 42, 77-82	36.3	280
119	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4616-20	2.2	277
118	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3000-10	15.9	268
117	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , 2011 , 13, 1364-9	1	268
116	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. <i>Modern Pathology</i> , 2008 , 21 Suppl 2, S16-22	9.8	268
115	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1472-8	2.2	257
114	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. <i>PLoS Medicine</i> , 2007 , 4, e294	11.6	252
113	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. <i>Clinical Cancer Research</i> , 2007 , 13, 5150-5	12.9	252
112	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. <i>Nature Genetics</i> , 2012 , 44, 1330-5	36.3	237
111	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3825-31	2.2	229
110	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 7519-25	12.9	227
109	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 18351-6	11.5	226
108	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 111-6	8.9	224

107	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. <i>Clinical Cancer Research</i> , 2005 , 11, 7841-50	12.9	224
106	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naïve non-small-cell lung cancer receiving first-line gefitinib monotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2745-53	2.2	222
105	Genetic predictors of MEK dependence in non-small cell lung cancer. <i>Cancer Research</i> , 2008 , 68, 9375-83	10.1	216
104	Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. <i>JAMA Oncology</i> , 2015 , 1, 88-96	13.4	207
103	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. <i>Cancer Research</i> , 2015 , 75, 2489-500	10.1	206
102	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. <i>Journal of Molecular Diagnostics</i> , 2005 , 7, 396-403	5.1	200
101	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 9435-40	11.5	196
100	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 5, S1-32; quiz S33	7.3	195
99	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014 , 20, 1027-34	50.5	191
98	Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. <i>Cancer Research</i> , 2008 , 68, 5524-8	10.1	185
97	Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1700-4	2.2	184
96	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. <i>Journal of Neuro-Oncology</i> , 2010 , 99, 283-6	4.8	181
95	Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1752-64	6.7	179
94	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. <i>Cancer Research</i> , 2011 , 71, 4920-31	10.1	174
93	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016 , 22, 4837-4847	12.9	168
92	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. <i>PLoS ONE</i> , 2011 , 6, e28204	3.7	161
91	A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. <i>Journal of Molecular Diagnostics</i> , 2011 , 13, 74-84	5.1	155
90	Practical management of patients with non-small-cell lung cancer treated with gefitinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 165-74	2.2	150

89	EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. <i>Journal of Molecular Diagnostics</i> , 2008 , 10, 242-8	5.1	149
88	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. <i>Clinical Cancer Research</i> , 2012 , 18, 1947-53	12.9	140
87	Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. <i>Clinical Cancer Research</i> , 2009 , 15, 6790-9	12.9	139
86	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. <i>Clinical Cancer Research</i> , 2008 , 14, 7060-7	12.9	135
85	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. <i>Genome Medicine</i> , 2013 , 5, 91	14.4	125
84	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. <i>Cancer</i> , 2013 , 119, 356-62	6.4	122
83	Lung cancer in never smokers: molecular profiles and therapeutic implications. <i>Clinical Cancer Research</i> , 2009 , 15, 5646-61	12.9	122
82	Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. <i>Clinical Cancer Research</i> , 2009 , 15, 5184-90	12.9	115
81	Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. <i>Cancer Discovery</i> , 2014 , 4, 1398-405	24.4	112
80	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). <i>PLoS ONE</i> , 2009 , 4, e7273	3.7	109
79	A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1435-7	8.9	106
78	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. <i>Clinical Cancer Research</i> , 2011 , 17, 2521-7	12.9	103
77	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 569-75	8.9	102
76	FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 4107-14	12.9	101
75	Characteristics of lung cancers harboring NRAS mutations. <i>Clinical Cancer Research</i> , 2013 , 19, 2584-91	12.9	100
74	How genetically engineered mouse tumor models provide insights into human cancers. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2273-81	2.2	97
73	Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. <i>American Journal of Roentgenology</i> , 2010 , 194, 266-9	5.4	96
72	Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. <i>PLoS ONE</i> , 2007 , 2, e810	3.7	93

71	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. <i>Cancer</i> , 2007 , 110, 599-605	6.4	91
70	Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E3595-604	11.5	89
69	A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. <i>Clinical Cancer Research</i> , 2010 , 16, 4647-53	12.9	89
68	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. <i>Clinical Cancer Research</i> , 2013 , 19, 1894-901	12.9	83
67	Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. <i>Science Translational Medicine</i> , 2012 , 4, 120ps2	17.5	83
66	Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. <i>Chest</i> , 2010 , 137, 46-52	5.3	82
65	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. <i>Oncologist</i> , 2014 , 19, 616-22	5.7	80
64	Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1623-9	8.9	79
63	Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1130-5	8.9	79
62	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. <i>Cancer Research</i> , 2017 , 77, 2990-3000	10.1	75
61	Integration of molecular profiling into the lung cancer clinic. <i>Clinical Cancer Research</i> , 2009 , 15, 5317-22	12.9	73
60	A bioinformatics workflow for variant peptide detection in shotgun proteomics. <i>Molecular and Cellular Proteomics</i> , 2011 , 10, M110.006536	7.6	73
59	Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. <i>PLoS ONE</i> , 2007 , 2, e426	3.7	73
58	Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 85-9	8.9	71
57	A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1918-28	6.1	69
56	Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. <i>Clinical Cancer Research</i> , 2010 , 16, 755-63	12.9	69
55	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. <i>Cancer</i> , 2006 , 107, 1034-41	6.4	69
54	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1048-53	8.9	68

53	Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1128-31	8.9	67
52	MET Exon 14 Skipping in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016 , 21, 481-6	5.7	67
51	Translating genomic information into clinical medicine: lung cancer as a paradigm. <i>Genome Research</i> , 2012 , 22, 2101-8	9.7	64
50	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. <i>Cancer Research</i> , 2016 , 76, 305-18	10.1	60
49	Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1583-93	8.9	58
48	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. <i>International Journal of Cancer</i> , 2015 , 137, 311-9	7.5	55
47	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. <i>Cell Reports</i> , 2014 , 7, 999-1008	10.6	55
46	Targeting the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). <i>Seminars in Cancer Biology</i> , 2004 , 14, 33-40	12.7	55
45	Genetically informed lung cancer medicine. <i>Journal of Pathology</i> , 2011 , 223, 230-40	9.4	53
44	Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8764-9	11.5	53
43	Beyond histology: translating tumor genotypes into clinically effective targeted therapies. <i>Clinical Cancer Research</i> , 2014 , 20, 2264-75	12.9	51
42	Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. <i>Clinical Cancer Research</i> , 2011 , 17, 3500-6	12.9	49
41	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. <i>Cancer Informatics</i> , 2015 , 14, 19-31	2.4	48
40	Patterns and processes of somatic mutations in nine major cancers. <i>BMC Medical Genomics</i> , 2014 , 7, 11	3.7	47
39	Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 760-8	8.9	45
38	Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. <i>Clinical Cancer Research</i> , 2011 , 17, 6322-8	12.9	42
37	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. <i>Science Signaling</i> , 2016 , 9, ra33	8.8	41
36	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. <i>Genome Research</i> , 2013 , 23, 1434-45	9.7	41

35	Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. <i>Molecular Pharmaceutics</i> , 2011 , 8, 2069-79	5.6	40
34	MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. <i>Genome Biology</i> , 2014 , 15, 489	18.3	36
33	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. <i>Nucleic Acids Research</i> , 2010 , 38, 6985-96	20.1	36
32	Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. <i>Archives of Pathology and Laboratory Medicine</i> , 2009 , 133, 470-7	5	36
31	Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 426-35	12.9	32
30	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. <i>Human Molecular Genetics</i> , 2016 , 25, 620-9	5.6	32
29	Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. <i>American Journal of Roentgenology</i> , 2013 , 200, 475-83	5.4	27
28	NF- κ B drives acquired resistance to a novel mutant-selective EGFR inhibitor. <i>Oncotarget</i> , 2015 , 6, 42717-33	3.3	27
27	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 542-52	6.1	26
26	Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 84-93	8.9	24
25	Molecular predictors of response to chemotherapy in non-small cell lung cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 104-13	2.2	23
24	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. <i>Methods</i> , 2015 , 83, 118-27	4.6	22
23	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. <i>Respiratory Medicine</i> , 2013 , 107, 1755-62	4.6	20
22	Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. <i>Cell Reports</i> , 2014 , 7, 1824-32	10.6	19
21	New approaches to targeted therapy in lung cancer. <i>Proceedings of the American Thoracic Society</i> , 2012 , 9, 72-3		19
20	EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 805	8.9	16
19	Defining clinically relevant molecular subsets of lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58 Suppl 1, s11-5	3.5	16
18	EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 434-42	8.9	15

17	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. <i>Oncotarget</i> , 2015 , 6, 11357-68	3.3	13
16	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. <i>Lung Cancer</i> , 2017 , 113, 51-58	5.9	12
15	Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. <i>Acta Pharmacologica Sinica</i> , 2010 , 31, 647-8	8	11
14	Molecular on/off switch. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4940-2	2.2	11
13	A new target for therapy in squamous cell carcinoma of the lung. <i>Cancer Discovery</i> , 2011 , 1, 23-4	24.4	10
12	Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. <i>Cancer Discovery</i> , 2015 , 5, 348-50	24.4	9
11	Maximizing the benefits of off-target kinase inhibitor activity. <i>Cancer Discovery</i> , 2013 , 3, 138-40	24.4	9
10	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015 , 6, 22348-60	3.3	8
9	EGFR mutant lung cancer. <i>Current Topics in Microbiology and Immunology</i> , 2012 , 355, 59-81	3.3	5
8	CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016 , 23, 692-700	8.6	4
7	Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 5371-3	12.9	4
6	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?. <i>Cancer Biology and Therapy</i> , 2005 , 4, 1096-7	4.6	4
5	Melanoma BRAF fusions--response. <i>Clinical Cancer Research</i> , 2014 , 20, 6632	12.9	3
4	BAC Consensus Conference, November 4-6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S2-S7	8.9	2
3	Clinical Applications of Kinase Inhibitors in Solid Tumors 2010 , 615-631		1
2	BAC Consensus Conference, November 4-6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S2-S7	8.9	1
1	Biology of Lung Cancer 2016 , 912-926.e6		0